Table 3.

Risk of epithelial ovarian cancer associated with exclusive use of ET, EPT, and CC-EPT hormone therapy

ET
EPT
CC-EPT
Controls, nCases, nOR* (95% CI)Controls, nCases, nOR* (95% CI)Controls, nCases, nOR* (95% CI)
Never used6144401.06144401.06144401.0
Ever1671211.3 (0.9-1.7)3221540.8 (0.6-1.0)215940.7 (0.5-1.0)
Duration of use
    <60 mo67380.9 (0.6-1.5)131510.6 (0.4-0.8)88330.6 (0.4-0.9)
    60-119 mo26211.3 (0.7-2.5)83501.0 (0.6-1.5)61350.9 (0.6-1.4)
    120+ mo74621.6 (1.1-2.5)108530.9 (0.6-1.3)66260.7 (0.4-1.2)
Recency
    Current users84641.3 (0.9-2.0)123841.1 (0.8-1.5)82541.0 (0.7-1.5)
    Former users83571.2 (0.8-1.8)199700.6 (0.4-0.8)133400.5 (0.3-0.7)
        Recently quit (6-35 mo ago)27211.5 (0.8-2.8)95400.7 (0.4-1.0)69260.6 (0.4-1.0)
        Quit ≥3 y ago (36+ mo)56361.1 (0.7-1.7)104300.5 (0.3-0.7)64140.4 (0.2-0.7)
Duration of use
    Among current users
        <60 mo1990.7 (0.3-1.5)38240.9 (0.5-1.6)26181.0 (0.5-1.9)
        60+ mo65551.6 (1.1-2.5)85601.1 (0.8-1.7)56361.0 (0.6-1.7)
    Among recently quit
        <60 mo1061.2 (0.4-3.4)24110.7 (0.3-1.5)1880.7 (0.3-1.6)
        60+ mo17151.8 (0.8-3.7)71290.7 (0.4-1.1)51180.6 (0.3-1.0)
    Among quit ≥3 y ago
        <60 mo38231.1 (0.6-1.9)69160.3 (0.2-0.6)4470.2 (0.1-0.6)
        60+ mo18131.2 (0.6-2.7)35140.7 (0.4-1.4)2070.7 (0.3-1.6)
  • * Odds ratios adjusted for age, county of residence, year of diagnosis/reference date, number of full-term pregnancies, and duration of hormonal contraception.